Handbook of Gastrointestinal Cancer
Format: PDF / Kindle (mobi) / ePub
Do you manage patients with gastrointestinal cancer?
Do you need a rapid reference handbook to guide you through your diagnosis and management options?
If so, then Handbook of Gastrointestinal Cancer is the book for you, providing clear, practical guidance to the diagnosis and clinical management of all forms of GI cancer, in a highly accessible format. Perfect for GI/Oncology trainees and junior gastroenterologists/oncologists and designed for point-of-care consultation, each chapter is structured in a uniform way and contains a variety of handy text features to help the reader such as case histories, key practice points, key weblinks and potential pitfalls
The authors emphasize the best clinical assessment and management methods of patients and dedicate an entire chapter to each cancer, from esophageal to lower GI, and from biliary to pancreatic cancer.
This attractive new book features:
- Comprehensive yet quick and easy display of key points
- Case studies to illustrate cardinal lessons or dilemmas
- A fully integrated GI/oncologic approach
- An outstanding and international editor and author team of great experience
- Illustrations of key clinical or investigative features
Handbook of Gastrointestinal Cancer answers all your clinical needs and is a must-have tool on the ward for all trainee and junior gastroenterologists and oncologists.
"Handbook of GI Cancer ... does an excellent job of indicating which clinical recommendations are solidly evidence-based, and highlighting those that would benefit from further research."
—Monica M. Bertagnolli, MD, Chief, Division of Surgical Oncology, Dana Farber/Brigham and Women's Cancer Center, Boston, USA
"Handbook of Gastrointestinal Cancer is a comprehensive text that should be on the bookshelf of every physician and surgeon who deals with GI malignancies. The editors, who are internationally renowned, have assembled an all-star cast of contributing authors from around the world. The inclusion of key points and case studies, and the use of an evidence-based approach, make this a stand-out reference."
—Mark K. Ferguson, MD,Professor, Department of Surgery and The Cancer Research Center, The University of Chicago Medicine & Biological Sciences, Chicago, USA
supported by an ovarian-type stroma.79 They almost always arise de novo and are often located in the body tail of the pancreas.79,80 They often present with vague symptoms of abdominal pain, weight loss, nausea, and vomiting. The presence of calcifications and multiseptae distinguish this from other cysts.78 The imaging triad of calcifications, thick walls, and mural vegetation on CT scanning is predictive of malignant degeneration in up to 95% of cases.81 A combination of cross-sectional
eggs, meat, and central water supply. The risk factors for this high incidence are still to be further elucidated, but they likely include cigarette smoking, pipe smoking, excessive alcohol use, dietary habits (vitamin deficiency, etc.), differences in cooking, and environmental exposure. In Linxian, China, for example, high levels of polycyclic aromatic hydrocarbons have been found in the food that implicates cooking fuels as a potential source of this carcinogen in this high-risk area. It is
chemotherapy. • Small cancers: to determine candidacy for transanal excision. Potential impact of EUS staging on rectal cancer management75 • uT1: transanal local resection. • uT2: radical resection ± postoperative radiation. • uT3–4 or uN1: preoperative chemoradiation before radical resection. FDG-PET FDG is a glucose analog and its uptake reflects cellular metabolism, which is increased in many tumors.63 But it is also accumulated in activated inflammatory cells such as granulocytes and
Handbook of Gastrointestinal Cancer, First Edition. Edited by Janusz Jankowski and Ernest Hawk. © 2013 John Wiley & Sons, Ltd. Published 2013 by John Wiley & Sons, Ltd. 137 138 Handbook of Gastrointestinal Cancer • Concurrent radiation therapy and chemotherapy can provide long-term disease-free survival in the management of squamous cell anal cancer, and requires close monitoring of acute and late toxicities. Epidemiology Prior to reviewing the epidemiology of anal cancer, one must first
is reported to have a sensitivity of 65–80% and specificity of more than 90% when used for screening. Its performance characteristics are negatively impacted by the presence of cirrhotic nodules, subject obesity, and operator inexperience. However, its easy availability and relative cost-efficacy make it the test of choice for surveillance. Surveillance intervals should be between 6 and 12 months based on reported tumor doubling times. The latest update to the AASLD practice guidelines for